$EFX

Equifax agreed to a $100 million settlement over a 2022 coding error that misreported credit scores for 4 million people. The settlement, pending final court approval, aims to compensate affected consumers who may have faced higher interest rates or denials. Equifax denies wrongdoing. Claims are not yet open, with a final hearing scheduled for January 22, 2027.

Equifax (EFX) stock has underperformed the broader market and its industry benchmark, with a 23.7% decline over the past year. Analysts expect EPS growth of 12.2% for the current year, with a consensus 'Moderate Buy' rating and a mean price target of $208.77, suggesting a 7.3% upside. The company's profitability has declined, with a 3.6% drop in adjusted operating margin over five years.

CoStar (CSGP) reported Q2 revenue of $925M, up 18.4% YoY, meeting expectations but delivering the weakest guidance among peers. EXL (EXLS) outperformed with $594.8M revenue, up 15.6% YoY, and raised full-year guidance. Equifax (EFX) and TransUnion (TRU) also reported, with TRU raising guidance. The sector saw mixed results, with revenues 1% above consensus but next quarter's guidance 1.3% below. Stocks are up 7.8% on average since earnings.

Equifax agreed to a $100 million settlement over miscalculated credit scores for 4 million consumers in 2022. The settlement awaits court approval. Equifax denies wrongdoing. Affected consumers may receive payments after deductions.

Equifax received preliminary approval for a $100M settlement over a 2022 coding error that miscalculated credit scores for 4M consumers. The error, which lasted three weeks, caused significant score drops, affecting loan applications. The settlement, the largest under the Fair Credit Reporting Act, will be distributed to affected consumers. A final approval hearing is scheduled for January 22, 2027.

Deutsche Bank analyst Faiza Alwy identified top Business and Info Services stocks post-Q2 earnings. Aramark (ARMK) and TransUnion (TRU) raised outlooks, while CoStar Group (CSGP) lowered guidance. Equifax (EFX) and Fair Isaac (FICO) beat EPS estimates. Moody’s (MCO) and S&P Global (SPGI) surpassed revenue and profit forecasts. Republic Services (RSG) and Trinity Health (TH) showed upside potential. Deutsche Bank upgraded Trinity Health (TH) to Buy.

Analysts upgraded five companies: Baird raised Parsons (PSN) to Outperform with a $57 target; Keybanc upgraded InnovAge (INNV) to Overweight with a $13 target; Rothschild upgraded Equifax (EFX) to Buy with a $235 target; JPMorgan upgraded TIC Solutions (TIC) to Neutral with an $11 target; Morgan Stanley upgraded Ternium (TX) to Overweight with a $65 target.

Analysts upgraded Equifax (EFX) to Buy with a $235 target, Parsons (PSN) to Outperform with a $57 target, Taylor Devices (TAYD) to Buy with a $70 target, Ternium (TX) to Overweight with a $65 target, and O-I Glass (OI) to Buy with a $9 target. Teradyne (TER) was downgraded to Neutral, Ternium (TX) to Hold, Limbach (LMB) to Underweight, DoubleVerify (DV) to Neutral, and Weibo (WB) to Neutral. Nvidia (NVDA) was initiated with an Outperform rating and $340 target, Micron (MU) with Outperform and $1

Analysts updated price targets for several companies. Baird raised Ross Stores (ROST) target to $270, Parsons (PSN) to $57, and Deere (DE) to $640. BTIG cut Walmart (WMT) target to $140. HSBC raised Ternium (TX) target to $55. Rothschild & Co increased Equifax (EFX) target to $235. Other changes include Envoy Medical (COCH), MDxHealth (MDXH), Hometrust Bancshares (HTB), and Haemonetics (HAE).

Wall Street analyst research calls include upgrades for Equifax (EFX), O-I Glass (OI), Portland General Electric (POR), Taylor Devices (TAYD), and Ternium (TX), with downgrades for Bowman Consulting (BWMN), Limbach Holdings (LMB), Teradyne (TER), Frontline (FRO), and Weibo (WB). Initiations include Broadcom (AVGO), Hubbell (HUBB), Marvell Technology (MRVL), NVIDIA (NVDA), and SpaceX (SPCX). Markets saw mixed performance with tech and small-cap indices declining, while oil and crypto prices rose.